SYMBICORT AEROSPHERE Drug Patent Profile

Which patents cover Symbicort Aerosphere, and what generic alternatives are available?

Symbicort Aerosphere is a drug marketed by Astrazeneca and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in SYMBICORT AEROSPHERE is budesonide; formoterol fumarate. There is one drug master file entry for this compound. Additional details are available on the budesonide; formoterol fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Symbicort Aerosphere

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 27, 2029. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SYMBICORT AEROSPHERE

US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SYMBICORT AEROSPHERE
DailyMed Link:	SYMBICORT AEROSPHERE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SYMBICORT AEROSPHERE

Constraining patent/regulatory exclusivity:

NEW STRENGTH

NDA:

216579

Dosage:

AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for SYMBICORT AEROSPHERE

SYMBICORT AEROSPHERE is protected by four US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on NEW STRENGTH.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-002	Apr 27, 2026		RX	Yes	Yes	9,415,009
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-001	Apr 28, 2023		RX	Yes	Yes	10,716,753		Y
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-001	Apr 28, 2023		RX	Yes	Yes
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-002	Apr 27, 2026		RX	Yes	Yes	10,716,753		Y

International Patents for SYMBICORT AEROSPHERE

When does loss-of-exclusivity occur for SYMBICORT AEROSPHERE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Montenegro

Norway

Philippines

Poland

Portugal

Russian Federation

San Marino

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SYMBICORT AEROSPHERE around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	076621
Argentina	076806
Argentina	076807
Argentina	121758

Supplementary Protection Certificates for SYMBICORT AEROSPHERE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0613371	SPC/GB02/033	United Kingdom		PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
2435025	300995	Netherlands		PRODUCT NAME: COMBINATIE VAN GLYCOPYRRONIUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER GLYCOPYRRONIUYM BROMIDE, EN FORMOTEROL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER FORMOTEROL FUMARAAT DIHYDRAAT; REGISTRATION NO/DATE: EU/ 1/18/1339 20181220
2435025	PA2019014	Lithuania		PRODUCT NAME: GLIKOPIROLATO (ISKAITANT BET KOKIAS JO FARMACINIU POZIURIU PRIIMTINAS DRUSKAS, ESTERIUS, ENANTIOMERUS AR KITUS DARINIUS) IR FORMOTEROLIO (ISKAITANT BET KOKIAS JO FARMACINIU POZIURIU PRIIMTINAS DRUSKAS, ESTERIUS, ENANTIOMERUS AR KITUS DARINIUS) DERINYS; REGISTRATION NO/DATE: EU/1/18/1339 20181218
2435025	122019000068	Germany		PRODUCT NAME: KOMBINATION VON GLYCOPYRROLAT, EINSCHLIESSLICH BELIEBIGER PHARMAZEUTISCH VERTRAEGLICHER SALZE, ESTER, ENANTIOMERE, ODER ANDERER DERIVATE DAVON, UND FORMOTEROL, EINSCHLIESSLICH BELIEBIGER PHARMAZEUTISCH VERTRAEGLICHER SALZE, ESTER, ENANTIOMERE, ODER ANDERER DERIVATE DAVON; REGISTRATION NO/DATE: EU/1/18/1339 20181218

SYMBICORT AEROSPHERE market dynamics and financial trajectory: revenue drivers, competitive threats, and exclusivity-to-generic risk

Last updated: July 28, 2026

Executive summary: Symbicort Aerosphere (budesonide/formoterol fumarate dihydrate inhalation aerosol) is a long-running, global chronic respiratory therapy with steady demand tied to COPD and asthma guideline adherence, payer formulary placement, and channel inventory cycles. Near-term dynamics are driven by (1) unit growth or share shifts in combination ICS/LABA inhalers, (2) payer preference for specific device formats, and (3) competitor pricing after generic and authorized generic erosion across the ICS/LABA category. Longer-horizon financial trajectory hinges on patent and exclusivity expiry for the specific “Aerosphere” delivery system (and any method-of-use/formulation/device patents), the strength of the Orange Book patent estate, and whether challengers file Paragraph IV certifications or resolve via settlements that accelerate generic entry.

---

What drives Symbicort Aerosphere sales and market share in asthma and COPD?

Symbicort Aerosphere competes within the ICS/LABA inhaler class where prescriber behavior, inhaler technique, and formulary design typically govern retention more than pharmacologic differentiation. For chronic asthma and COPD, the commercial pattern is dominated by maintenance use, adherence, and step-therapy constructs.

How do payer design and step-therapy affect Symbicort Aerosphere revenue?

High-level payer mechanics that consistently affect branded ICS/LABA inhalers:

• Formulary tiering: net sales depend more on preferred tier placement than headline list price.
• Step-edit rules: insurers often require trials of preferred alternatives before authorizing a specific branded inhaler.
• Prior authorization (PA) and quantity limits: can delay initiation and shift patients to other devices.
• Copay assistance constraints: manufacturer-sponsored programs influence patient persistence but face increasing payer scrutiny and policy caps.

For Symbicort Aerosphere, device format can matter in managed care because payers prefer established contracting lanes per device category (metered-dose inhaler vs. dry powder inhaler vs. specific delivery technologies).

Which patient populations support the commercial base?

• Asthma: maintenance controller therapy; growth depends on stable diagnosis rates and adherence to stepwise escalation.
• COPD: maintenance bronchodilation with anti-inflammatory effect; uptake depends on COPD severity coding, spirometry practices, and guideline alignment.

What role does inhaler technique and device preference play?

Inhaler usability is a binding commercial variable. Patients who perceive better handling and correct dose delivery keep the therapy. Payers also respond to observed persistence: a device associated with better adherence typically retains share after formulary renewals.

---

How competitive is the Symbicort Aerosphere inhaler market, and who pressures pricing?

What are the main competitive categories?

Symbicort Aerosphere is pressured by multiple competitive vectors:

• Other ICS/LABA brands and authorized product line extensions across asthma and COPD.
• Generic and authorized generic ICS/LABA formulations depending on the patent landscape for specific actives and dosage forms.
• Formulary substitution to LABA/LAMA or triple therapy in COPD where outcomes and formulary incentives push escalation.

What is the typical pricing and net-to-gross compression pattern for mature ICS/LABA brands?

As category competition intensifies, Symbicort Aerosphere revenue typically faces:

• higher rebates to secure formulary placement,
• greater patient steering to preferred devices,
• and increased share loss in states and plan groups where net price competition is aggressive.

The magnitude depends on whether competitors offer materially lower net pricing through authorized generics or device-positioning strategies.

---

When does Symbicort Aerosphere lose exclusivity, and what is the generic entry risk timeline?

Featured snippet answer: Symbicort Aerosphere’s exclusivity risk is determined by the specific Orange Book patent(s) tied to the Aerosphere product, including formulation, method-of-use, and device-related claims. Generic and authorized-generic entry timing hinges on the last expiring patent and whether Paragraph IV litigation settles early.

What determines exclusivity timing for the Aerosphere product specifically?

For branded inhalation aerosols, exclusivity is not only about the patent on the combination actives. Commercially relevant risk usually comes from:

• Orange Book listed patents for formulation/device and any method-of-use indications,
• pediatric exclusivity extensions when applicable,
• or market exclusivity tied to an approval pathway for a specific strength, indication, or formulation.

How does settlement structure affect entry speed?

Inhaler category settlements often trade:

• launch timing for shared revenue or stipulated payments,
• or “no design-around” commitments that reduce workaround risk.

If an early settlement is reached, generic launch can occur quickly even if other patent claims remain active.

---

What patents protect Symbicort Aerosphere, and how strong is the patent estate?

A complete patent-strength assessment requires Orange Book patent lists for the specific Symbicort Aerosphere NDA/strength and related litigation dockets. Without those listings and case records in the current input, a full patent-count and expiration table would risk being inaccurate.

Given the requirement for hard data, this analysis does not populate:

• specific patent numbers and expiration dates,
• assignees,
• remaining claim scope,
• or litigation status.

---

What is the Orange Book status of Symbicort Aerosphere, and are there Paragraph IV challenges?

Featured snippet answer: Orange Book status and Paragraph IV presence are definitive inputs for entry timing and settlement likelihood, but they are not provided in the current input.

No Orange Book table, challenger list, or certification history is included.

---

How does Symbicort Aerosphere compare with other ICS/LABA inhalers on commercial resilience?

Which comparison dimensions matter most in market dynamics?

• Net retention: continuation rates and persistence.
• Formulary position across top payers: preferred tiers.
• Device contracting: payers often standardize across devices.
• Channel management: inventory cycles around respiratory seasonal demand.

Where brands typically outperform generics in inhaler markets

Even after generic entry of one strength or label variant, brands can sustain revenue if they:

• retain preferred contracting for other strengths or delivery formats,
• maintain patient support programs,
• and demonstrate lower discontinuation rates tied to device performance.

Where brands typically lose fastest

Brands typically lose share when:

• authorized generics enter simultaneously across strengths,
• PBMs implement aggressive switching rules,
• and device advantages become less relevant once a preferred plan incumbent is established.

---

What generic launch scenarios could impact Symbicort Aerosphere revenue?

Scenario categories insurers and PBMs usually follow

1. Strength-by-strength entry: generic launch may begin with specific strengths or package sizes that clear the patent barrier first.
2. Authorized generic substitution: a close launch from an AB-rated product can compress branded pricing without immediate litigation leverage.
3. Device or formulation workarounds: if competitors argue that their product design avoids certain device/formulation claims, entry may accelerate even if some patents remain active.

Revenue impact mechanisms

• immediate net price compression,
• share shift away from the branded device,
• and rebate realignment to preserve remaining formulary placement.

---

How do COPD and asthma guideline shifts affect Symbicort Aerosphere financial trajectory?

Asthma maintenance dynamics

Asthma controller adoption correlates with:

• diagnosis rates,
• clinician step-therapy practices,
• and guideline updates that define controller initiation thresholds.

For mature brands, growth is usually incremental and depends on adherence and switching patterns.

COPD dynamics

COPD maintenance therapy has shifted toward combination bronchodilation and triple therapy in many formularies. That reduces potential headroom for ICS/LABA-only regimens unless the product maintains a strong position in:

• exacerbation-prone patient subsets,
• and specific payer pathways that still favor ICS/LABA before triple therapy.

---

Key commercial KPIs to monitor for Symbicort Aerosphere going forward

Even without NDA-specific patent tables, business decision-making can be tracked through measurable market KPIs:

• Prescription share by inhaler class (ICS/LABA and ICS/LABA+LAMA crossovers).
• Unit market share by device format (pressurized MDI vs alternatives).
• Net price and rebate intensity (net sales erosion post-competitive entry).
• Persistence and adherence proxies (refill patterns).
• PBM formulary changes (tier movement, PA requirements, switching edits).
• Seasonality (respiratory peaks affecting demand).

---

Key Takeaways

• Symbicort Aerosphere demand is anchored in chronic asthma and COPD maintenance therapy, with revenue sensitivity driven by payer formulary placement and device preference.
• Competitive pressure in ICS/LABA inhalers increasingly comes from generic/authorized generic entry, authorized therapeutic substitutions, and COPD step-up to triple therapy pathways.
• The generic entry timetable and potential revenue compression depend on Aerosphere-specific Orange Book-listed patents and any Paragraph IV challenges and settlement outcomes.
• The most decision-relevant forward-looking variables are net price compression, formulary tier position, device-based switching dynamics, and the timing of last-expiring patent protection for the Aerosphere product variant.

---

FAQs

1. How does PBM step therapy typically affect branded ICS/LABA inhalers like Symbicort Aerosphere?
2. What are the main indicators that Symbicort Aerosphere is losing share to authorized generics or competing devices?
3. How do changes in COPD guideline adoption of triple therapy alter the market size for ICS/LABA inhalers?
4. What settlement structures most often accelerate generic entry for inhalation aerosol combinations?
5. How do inhaler device usability and adherence metrics correlate with long-term revenue retention for mature respiratory brands?

---

References (APA)

1. (No cited sources were provided in the current input.)